Expert Perspectives: Navigating the Evolving Treatment Landscape in Early Relapse MM

Author(s):

Robert Z. Orlowski, MD, PhDJonathan L. Kaufman, MD

The panelists explore the evolution of treatment approaches for patients with relapsed/refractory multiple myeloma who have undergone 1-3 lines of therapy, with a particular focus on the implications of increased anti-CD38 monoclonal antibody usage in newly diagnosed or early relapse cases.

EP: 1.Clinical Scenario I: 68-yr Old Man with Early Relapse MM

EP: 2.Clinical Insights on Next Treatment Approach Steps

EP: 3.Real Life Clinical Practice Use of Selinexor: Dosing Strategies, Supportive Care, and Strategies to Incorporate into Novel Selinexor-Based Regimens

Now Viewing

EP: 4.Expert Perspectives: Navigating the Evolving Treatment Landscape in Early Relapse MM

EP: 5.Overview of CAR T-cell Therapy Options in R/R MM

EP: 6.Expert Perspectives: Selinexor Role in the Changing Treatment Landscape in MM and Key Takeaways

EP: 7.Patient Profile: 53-Year-Old Man with Heavily Pre-Treated MM including T-cell Directed Therapy

EP: 8.Clinical Insights on the Patient Presentation & Treatment Course

EP: 9.Challenges of Treatment Sequencing in Heavily Pre-Treated R/R MM: Expert Insights

EP: 10.Potential Novel Lab Monitoring & Key Takeaways for Heavily Pre-Treated R/R MM

Video content above is prompted by the following:

How has the treatment landscape evolved for patients with r/r MM, post 1-3 lines of therapy, especially in the setting of increasing use of anti-CD38 monoclonal antibodies in the newly diagnosed or early relapse space?
- What are currently available treatment options?
What is the utility of Selinexor in the post anti-CD38-monoclonal antibody setting?